Administered intravenously (IV) or intramuscularly (IM) by a healthcare professional. IV administration should be slow, over at least 2 minutes. Continuous IV infusion requires a controlled infusion device.

Midazolam enhances the effect of gamma-aminobutyric acid (GABA), the major inhibitory neurotransmitter in the central nervous system, by binding to benzodiazepine receptors on the GABA-A receptor complex. This action leads to increased chloride ion influx, neuronal hyperpolarization, and decreased neuronal excitability, resulting in its sedative, anxiolytic, and anticonvulsant effects.

• •Hypersensitivity to Midazolam or other benzodiazepines.
• •Acute narrow-angle glaucoma.
• •Severe respiratory depression, especially without ventilatory support.
• •Patients in shock or coma.

Store below 30°C (86°F). Do not freeze. Protect from light. Keep out of reach of children.

Symptoms include somnolence, confusion, impaired coordination, diminished reflexes, coma, and respiratory depression. Management involves supportive care, maintaining airway, and administering flumazenil (benzodiazepine antagonist) if severe respiratory depression or sedation occurs.

Pregnancy: Category D. Can cause fetal harm. Increased risk of congenital malformations in the first trimester. If used late in pregnancy, can cause neonatal flaccidity, respiratory depression, feeding difficulties, and withdrawal symptoms. Lactation: Excreted in breast milk. Use with caution. Advise mothers to avoid breastfeeding for at least 4-6 hours after a single dose.